{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:05:05Z","timestamp":1787169905243,"version":"build-2736575974"},"reference-count":323,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Postgraduate Research Institute of Science, Technology, Environment and Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The supply and control of iron is essential for all cells and vital for many physiological processes. All functions and activities of iron are expressed in conjunction with iron-binding molecules. For example, natural chelators such as transferrin and chelator\u2013iron complexes such as haem play major roles in iron metabolism and human physiology. Similarly, the mainstay treatments of the most common diseases of iron metabolism, namely iron deficiency anaemia and iron overload, involve many iron\u2013chelator complexes and the iron-chelating drugs deferiprone (L1), deferoxamine (DF) and deferasirox. Endogenous chelators such as citric acid and glutathione and exogenous chelators such as ascorbic acid also play important roles in iron metabolism and iron homeostasis. Recent advances in the treatment of iron deficiency anaemia with effective iron complexes such as the ferric iron tri-maltol complex (feraccru or accrufer) and the effective treatment of transfusional iron overload using L1 and L1\/DF combinations have decreased associated mortality and morbidity and also improved the quality of life of millions of patients. Many other chelating drugs such as ciclopirox, dexrazoxane and EDTA are used daily by millions of patients in other diseases. Similarly, many other drugs or their metabolites with iron-chelation capacity such as hydroxyurea, tetracyclines, anthracyclines and aspirin, as well as dietary molecules such as gallic acid, caffeic acid, quercetin, ellagic acid, maltol and many other phytochelators, are known to interact with iron and affect iron metabolism and related diseases. Different interactions are also observed in the presence of essential, xenobiotic, diagnostic and theranostic metal ions competing with iron. Clinical trials using L1 in Parkinson\u2019s, Alzheimer\u2019s and other neurodegenerative diseases, as well as HIV and other infections, cancer, diabetic nephropathy and anaemia of inflammation, highlight the importance of chelation therapy in many other clinical conditions. The proposed use of iron chelators for modulating ferroptosis signifies a new era in the design of new therapeutic chelation strategies in many other diseases. The introduction of artificial intelligence guidance for optimal chelation therapeutic outcomes in personalised medicine is expected to increase further the impact of chelation in medicine, as well as the survival and quality of life of millions of patients with iron metabolic disorders and also other diseases.<\/jats:p>","DOI":"10.3390\/ijms25094654","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:08:32Z","timestamp":1714032512000},"page":"4654","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-7340","authenticated-orcid":false,"given":"George J.","family":"Kontoghiorghes","sequence":"first","affiliation":[{"name":"Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol 3021, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02829934","article-title":"A precious metal: Iron, an essential nutrient for all cells","volume":"1","author":"Cairo","year":"2006","journal-title":"Genes Nutr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100866","DOI":"10.1016\/j.mam.2020.100866","article-title":"Basics and principles of cellular and systemic iron homeostasis","volume":"75","author":"Katsarou","year":"2020","journal-title":"Mol. Asp. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gozzelino, R., and Arosio, P. (2016). Iron Homeostasis in Health and Disease. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010130"},{"key":"ref_4","first-page":"93","article-title":"Zinc: An overview","volume":"11","author":"Prasad","year":"1995","journal-title":"Nutrition"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1146\/annurev.bi.61.070192.004341","article-title":"Zinc proteins: Enzymes, storage proteins, transcription factors, and replication proteins","volume":"61","author":"Coleman","year":"1992","journal-title":"Annu. Rev. Biochem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.2741\/1424","article-title":"Copper storage diseases: Menkes, Wilsons, and cancer","volume":"9","author":"Daniel","year":"2004","journal-title":"Front. Biosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/bmj.326.7386.409","article-title":"Zinc deficiency","volume":"326","author":"Prasad","year":"2003","journal-title":"BMJ"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Baldari, S., Di Rocco, G., and Toietta, G. (2020). Current Biomedical Use of Copper Chelation Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031069"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1039\/C8MT00219C","article-title":"Is copper a new target to counteract the progression of chronic diseases?","volume":"10","author":"Balsano","year":"2018","journal-title":"Metallomics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJM199912233412607","article-title":"Disorders of iron metabolism","volume":"341","author":"Andrews","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J., and Kontoghiorghe, C.N. (2020). Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells, 9.","DOI":"10.3390\/cells9061456"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1017\/S1368980008002401","article-title":"Worldwide Prevalence of Anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993\u20132005","volume":"12","author":"McLean","year":"2009","journal-title":"Public Health Nutr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(20)32594-0","article-title":"Iron deficiency","volume":"397","author":"Pasricha","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tardy, A.L., Pouteau, E., Marquez, D., Yilmaz, C., and Scholey, A. (2020). Vitamins and Minerals for Energy, Fatigue and Cognition: A Narrative Review of the Biochemical and Clinical Evidence. Nutrients, 12.","DOI":"10.3390\/nu12010228"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of Inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5982580","DOI":"10.1155\/2023\/5982580","article-title":"The Diagnostic Accuracy of a Fecal Immunochemical Test in Detecting Colorectal Cancer and Advanced Precancerous Colorectal Neoplasia in Patients with Iron Deficiency: A Protocol for Systematic Review and Meta-Analysis","volume":"2023","author":"Pham","year":"2023","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bao, H., Wang, Y., Xiong, H., Xia, Y., Cui, Z., and Liu, L. (2024). Mechanism of Iron Ion Homeostasis in Intestinal Immunity and Gut Microbiota Remodeling. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25020727"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40001-022-00922-6","article-title":"How to diagnose iron deficiency in chronic disease: A review of current methods and potential marker for the outcome","volume":"28","author":"Rohr","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Macdougall, I.C. (2023). Anaemia in CKD\u2014Treatment standard. Nephrol. Dial. Transplant., gfad250.","DOI":"10.1093\/ndt\/gfad250"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.2174\/092986705774463030","article-title":"Molecular factors and mechanisms affecting iron and other metal excretion or absorption in health and disease. The role of natural and synthetic chelators","volume":"12","author":"Kontoghiorghes","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Teixeira Farinha, H., Bouriez, D., Grimaud, T., Rotariu, A.M., Collet, D., Mantziari, S., and Gronnier, C. (2023). Gastro-Intestinal Disorders and Micronutrient Deficiencies following Oncologic Esophagectomy and Gastrectomy. Cancers, 15.","DOI":"10.3390\/cancers15143554"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3324\/haematol.2015.138255","article-title":"Dietary and Pharmacological Factors Affecting Iron Absorption in Mice and Man (Comment for a Letter to the Editor)","volume":"101","author":"Kontoghiorghe","year":"2016","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Barton, J.C., and Edwards, C.Q. (2000). Hemochromatosis: Genetics, Pathophysiology, Diagnosis and Treatment, Cambridge University Press.","DOI":"10.1017\/CBO9780511666476"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ijlh.12347","article-title":"Epidemiology and diagnostic testing for hemochromatosis and iron overload","volume":"37","author":"Adams","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ng0896-399","article-title":"A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis","volume":"13","author":"Feder","year":"1996","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMra031573","article-title":"Hereditary hemochromatosis\u2014A new look at an old disease","volume":"350","author":"Pietrangelo","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2036.2004.02024.x","article-title":"Targeted screening for hereditary haemochromatosis in high-risk groups","volume":"20","author":"Dubois","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","unstructured":"(1983). Community control of hereditary anaemias: Memorandum from a WHO meeting. Bull. World Health Org., 61, 63\u201380."},{"key":"ref_29","unstructured":"Modell, B., and Berdoukas, V. (1984). The Clinical Approach to Thalassaemia, Grune and Stratton."},{"key":"ref_30","first-page":"704","article-title":"Inherited haemoglobin disorders: An increasing global health problem","volume":"79","author":"Weatherall","year":"2001","journal-title":"Bull. World Health Organ."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/bjh.18671","article-title":"Thalassaemia\u2014A global view","volume":"201","author":"Hokland","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"271.e1","DOI":"10.1016\/j.jtct.2023.01.020","article-title":"Iron Overload Following Hematopoietic Stem Cell Transplantation: Prevalence, Severity, and Management in Children and Adolescents with Malignant and Nonmalignant Diseases","volume":"29","author":"Cattoni","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/17474086.2020.1719359","article-title":"How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?","volume":"13","author":"Kontoghiorghes","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.bbmt.2017.01.009","article-title":"Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation","volume":"23","author":"Shenoy","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","first-page":"CD011577","article-title":"Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders","volume":"2015","author":"Gu","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e30152","DOI":"10.1002\/pbc.30152","article-title":"Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004\u20132019","volume":"70","author":"Tang","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_37","first-page":"598","article-title":"Free radicals, antioxidants and human disease: Where are we now?","volume":"119","author":"Halliwell","year":"1992","journal-title":"J. Lab. Clin. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Galaris, D., Barbouti, A., and Pantopoulos, K. (2019). Iron homeostasis and oxidative stress: An intimate relationship. Biochim. Biophys. Acta Mol. Cell Res., 1866.","DOI":"10.1016\/j.bbamcr.2019.118535"},{"key":"ref_39","first-page":"459","article-title":"Some current insights into oxidative stress","volume":"59","year":"2010","journal-title":"Physiol. Res."},{"key":"ref_40","first-page":"161","article-title":"Prospects for introducing deferiprone as potent pharmaceutical antioxidant","volume":"1","author":"Kontoghiorghes","year":"2009","journal-title":"Front. Biosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.bbagen.2019.06.010","article-title":"Iron homeostasis and iron-regulated ROS in cell death, senescence and human diseases","volume":"1863","author":"Nakamura","year":"2019","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"604738","DOI":"10.3389\/fphys.2021.604738","article-title":"The Redox Balance and Membrane Shedding in RBC Production, Maturation, and Senescence","volume":"12","author":"Fibach","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Denisov, E.T., and Afanas\u2019ev, I.B. (2005). Oxidation and Antioxidants in Organic Chemistry and Biology, Taylor and Francis Group.","DOI":"10.1201\/9781420030853"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3109\/03630260903212233","article-title":"The role of labile iron in kidney disease and treatment with chelation","volume":"33","author":"Shah","year":"2009","journal-title":"Hemoglobin"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.2174\/092986705774463021","article-title":"Hemoglobin and myoglobin associated oxidative stress: From molecular mechanisms to disease States","volume":"12","author":"Reeder","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1089\/ars.2016.6803","article-title":"Redox and Peroxidase Activities of the Hemoglobin Superfamily: Relevance to Health and Disease","volume":"26","author":"Reeder","year":"2017","journal-title":"Antioxid. Redox Signal."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: An iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00018-016-2194-1","article-title":"Mechanisms of ferroptosis","volume":"73","author":"Cao","year":"2016","journal-title":"Cell Mol. Life Sci."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Li, G., Liang, Y., Yang, H., Zhang, W., and Xie, T. (2022). The Research Landscape of Ferroptosis in Cancer: A Bibliometric Analysis. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.841724"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41419-019-2064-5","article-title":"ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation","volume":"10","author":"Park","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","article-title":"Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/cdd.2015.158","article-title":"Ferroptosis: Process and function","volume":"23","author":"Xie","year":"2016","journal-title":"Cell Death Differ."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"877634","DOI":"10.3389\/fimmu.2022.877634","article-title":"Ferroptosis: A Critical Moderator in the Life Cycle of Immune Cells","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/cr.2016.95","article-title":"Ferroptosis is an autophagic cell death process","volume":"26","author":"Gao","year":"2016","journal-title":"Cell Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2201704","DOI":"10.1002\/smll.202201704","article-title":"A Triple Therapeutic Strategy with Antiexosomal Iron Efflux for Enhanced Ferroptosis Therapy and Immunotherapy","volume":"18","author":"Wang","year":"2022","journal-title":"Small"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1080\/15548627.2016.1187366","article-title":"Autophagy promotes ferroptosis by degradation of ferritin","volume":"12","author":"Hou","year":"2016","journal-title":"Autophagy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1002\/cmdc.202100334","article-title":"Autophagy-Dependent Ferroptosis as a Therapeutic Target in Cancer","volume":"16","author":"Liu","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"de Souza, I., Ramalho, M.C.C., Guedes, C.B., Osawa, I.Y.A., Monteiro, L.K.S., Gomes, L.R., and Rocha, C.R.R. (2022). Ferroptosis Modulation: Potential Therapeutic Target for Glioblastoma Treatment. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23136879"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Montero, J., Chichiarelli, S., Eufemi, M., Altieri, F., Saso, L., and Rodrigo, R. (2022). Ascorbate as a Bioactive Compound in Cancer Therapy: The Old Classic Strikes Back. Molecules, 27.","DOI":"10.3390\/molecules27123818"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10611","DOI":"10.1038\/s41598-022-14964-7","article-title":"Predicting prognosis and clinical features of the tumor microenvironment based on ferroptosis score in patients with breast cancer","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"103732","DOI":"10.1016\/j.critrevonc.2022.103732","article-title":"Molecular mechanisms of ferroptosis and its role in prostate cancer therapy","volume":"176","author":"Wang","year":"2022","journal-title":"Crit. Rev. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"105970","DOI":"10.1016\/j.oraloncology.2022.105970","article-title":"Ferroptosis: An emerging therapeutic target for oral cancer","volume":"131","author":"Balachander","year":"2022","journal-title":"Oral Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cbin.11804","article-title":"Role of ferroptosis in gastrointestinal tumors: From mechanisms to therapies","volume":"46","author":"Si","year":"2022","journal-title":"Cell Biol. Int."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chen, J., Wei, Z., Fu, K., Duan, Y., Zhang, M., Li, K., Guo, T., and Yin, R. (2022). Non-apoptotic cell death in ovarian cancer: Treatment, resistance and prognosis. Biomed. Pharmacother., 150.","DOI":"10.1016\/j.biopha.2022.112929"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"872883","DOI":"10.3389\/fonc.2022.872883","article-title":"The Role of Nonapoptotic Programmed Cell Death\u2014Ferroptosis, Necroptosis, and Pyroptosis\u2014In Pancreatic Ductal Adenocarcinoma Treatment","volume":"12","author":"Hsu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ma, S., Adzavon, Y.M., Wen, X., Zhao, P., Xie, F., Liu, M., and Ma, X. (2022). Novel Insights in the Regulatory Mechanisms of Ferroptosis in Hepatocellular Carcinoma. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.873029"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1152\/ajpcell.00148.2022","article-title":"Ferroptosis at the crossroads of tumor-host interactions, metastasis, and therapy response","volume":"323","author":"Yao","year":"2022","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"879317","DOI":"10.3389\/fphar.2022.879317","article-title":"Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges","volume":"13","author":"Nie","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2174\/1566524022666220509124608","article-title":"Ferroptosis and cancer immunotherapy","volume":"23","author":"Yin","year":"2022","journal-title":"Curr. Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Xu, B., Hu, N., Guo, Z., Bao, W., Shao, B., and Yang, W. (2022). Targeting the Macrophage-Ferroptosis Crosstalk: A Novel Insight into Tumor Immunotherapy. Front. Biosci., 27.","DOI":"10.31083\/j.fbl2707203"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/1120009X.2023.2177808","article-title":"Mechanisms and applications of ferroptosis-associated regulators in cancer therapy and drug resistance","volume":"35","author":"Guan","year":"2023","journal-title":"J. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Chang, X., and Miao, J. (2023). Ferroptosis: Mechanism and potential applications in cervical cancer. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1164398"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41419-022-04927-1","article-title":"Regulatory pathways and drugs associated with ferroptosis in tumors","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"992734","DOI":"10.3389\/fphar.2022.992734","article-title":"Ferroptosis: A mixed blessing for infectious diseases","volume":"13","author":"Xiao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"110107","DOI":"10.1016\/j.cbi.2022.110107","article-title":"The multifaceted role of ferroptosis in kidney diseases","volume":"365","author":"Lin","year":"2022","journal-title":"Chem. Interact."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41420-022-01183-2","article-title":"Emerging roles of ferroptosis in cardiovascular diseases","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"175133","DOI":"10.1016\/j.ejphar.2022.175133","article-title":"Therapeutic Insights on Ferroptosis in Parkinson\u2019s disease","volume":"930","author":"Thapa","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/ehf2.12958","article-title":"Fatal lymphocytic cardiac damage in coronavirus disease 2019 (COVID-19): Autopsy reveals a ferroptosis signature","volume":"7","author":"Jacobs","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2022). Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126735"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"164172","DOI":"10.1016\/j.scitotenv.2023.164172","article-title":"Chronic arsenic exposure induces ferroptosis via enhancing ferritinophagy in chicken livers","volume":"890","author":"Yu","year":"2023","journal-title":"Sci. Total Environ."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"108373","DOI":"10.1016\/j.pharmthera.2023.108373","article-title":"Molecular mechanisms of ferroptosis and their involvement in brain diseases","volume":"244","author":"Costa","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"19630","DOI":"10.1038\/s41598-022-24152-2","article-title":"Ferroptosis inhibition by deferiprone, attenuates myelin damage and promotes neuroprotection in demyelinated optic nerve","volume":"12","author":"Rayatpour","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wang, C., Xie, L., Xing, Y., Liu, M., Yang, J., Gao, N., and Cai, Y. (2023). Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone. PLoS Neglected Trop. Dis., 17.","DOI":"10.1371\/journal.pntd.0011607"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s10238-023-01012-5","article-title":"The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo","volume":"23","author":"Asperti","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2022). New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213990"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Liu, M., Zhang, L., Mo, Y., Li, J., Yang, J., Wang, J., Karrow, N.A., Wu, H., and Sun, L. (2023). Ferroptosis is involved in deoxynivalenol-induced intestinal damage in pigs. J. Anim. Sci. Biotechnol., 14.","DOI":"10.1186\/s40104-023-00841-4"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2020). Advances on Chelation and Chelator Metal Complexes in Medicine. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072499"},{"key":"ref_89","first-page":"659","article-title":"Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals","volume":"43","author":"Sheppard","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20841","DOI":"10.3390\/molecules201119725","article-title":"Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology","volume":"20","author":"Kontoghiorghe","year":"2015","journal-title":"Molecules"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.freeradbiomed.2018.06.037","article-title":"Transferrin and transferrin receptors update","volume":"133","author":"Kawabata","year":"2019","journal-title":"Free. Radic. Biol. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2174\/092986705774462969","article-title":"Structure\/function overview of proteins involved in iron storage and transport","volume":"12","author":"Sargent","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1359-6446(04)03333-1","article-title":"Transferrin: Structure, function and potential therapeutic actions","volume":"10","author":"Gomme","year":"2005","journal-title":"Drug Discov. Today"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood-2014-12-617571","article-title":"TfR2 links iron metabolism and erythropoiesis","volume":"125","author":"Pantopoulos","year":"2015","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0005-2795(76)90270-1","article-title":"The detection of four molecular forms of human transferrin during the iron binding process","volume":"453","author":"Makey","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_96","first-page":"91","article-title":"An intracellular transit iron pool","volume":"Volume 51","author":"Jacobs","year":"1976","journal-title":"Ciba Foundation Symposium 51-Iron Metabolism"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/iub.1621","article-title":"Ferritin, cellular iron storage and regulation","volume":"69","author":"Arosio","year":"2017","journal-title":"IUBMB Life"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"12223","DOI":"10.1021\/ic400484n","article-title":"Ferritin: The protein nanocage and iron biomineral in health and in disease","volume":"52","author":"Theil","year":"2013","journal-title":"Inorg. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1039\/C7MT00284J","article-title":"Mobilization of iron from ferritin: New steps and details","volume":"10","author":"La","year":"2018","journal-title":"Metallomics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1021\/acs.biochem.7b00024","article-title":"Iron Oxidation and Core Formation in Recombinant Heteropolymeric Human Ferritins","volume":"56","author":"Mehlenbacher","year":"2017","journal-title":"Biochemistry"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000496324","article-title":"Storage Iron Turnover from a New Perspective","volume":"141","author":"Saito","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0892-0354(92)90011-E","article-title":"Ferritin and hemosiderin in pathological tissues","volume":"5","author":"Iancu","year":"1992","journal-title":"Electron Microsc. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.tracli.2018.08.006","article-title":"Pathophysiology and classification of iron overload diseases; update 2018","volume":"26","author":"Brissot","year":"2019","journal-title":"Transfus. Clin. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/bjh.13820","article-title":"Ineffective erythropoiesis and regulation of iron status in iron loading anaemias","volume":"172","author":"Camaschella","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Gozzelino, R., Poli, M., and Arosio, P. (2019). Iron as Therapeutic Target in Human Diseases. Pharmaceuticals, 12.","DOI":"10.3390\/ph12040178"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00702-011-0588-7","article-title":"Ultrastructural aspects of iron storage, transport and metabolism","volume":"118","author":"Iancu","year":"2011","journal-title":"J. Neural Transm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3109\/15376516.2012.727198","article-title":"Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: Factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*","volume":"23","author":"Kolnagou","year":"2013","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/jmri.21666","article-title":"Spleen R2 and R2* in iron-overloaded patients with sickle cell disease and thalassemia major","volume":"29","author":"Brewer","year":"2009","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/bcmd.2002.0554","article-title":"Increased duodenal DMT-1 expression and unchanged HFE mRNA levels in HFE-associated hereditary hemochromatosis and iron deficiency","volume":"29","author":"Byrnes","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2017-05-786590","article-title":"Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin","volume":"131","author":"Aschemeyer","year":"2018","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cmet.2015.09.006","article-title":"Ironing out Ferroportin","volume":"22","author":"Drakesmith","year":"2015","journal-title":"Cell Metab."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41586-020-2668-z","article-title":"Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms","volume":"586","author":"Azumaya","year":"2020","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-med-043021-032816","article-title":"Hepcidin and Iron in Health and Disease","volume":"74","author":"Nemeth","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2015-12-639112","article-title":"Hepcidin in the diagnosis of iron disorders","volume":"127","author":"Girelli","year":"2016","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.4254\/wjh.v14.i11.1931","article-title":"Haemochromatosis revisited","volume":"14","author":"Alvarenga","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.3748\/wjg.14.6893","article-title":"Function of the hemochromatosis protein HFE: Lessons from animal models","volume":"14","author":"Pantopoulos","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3324\/haematol.2017.170720","article-title":"Ferroportin disease: Pathogenesis, diagnosis and treatment","volume":"102","author":"Pietrangelo","year":"2017","journal-title":"Haematologica"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2018-04-842997","article-title":"Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress","volume":"132","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1258\/0007142991902628","article-title":"Inborn errors of metabolism: Iron","volume":"55","author":"Worwood","year":"1999","journal-title":"Br. Med. Bull."},{"key":"ref_120","unstructured":"Moustarah, F., and Daley, S.F. (2024). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00421-019-04157-y","article-title":"Iron considerations for the athlete: A narrative review","volume":"119","author":"Sim","year":"2019","journal-title":"Eur. J. Appl. Physiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1111\/trf.12647","article-title":"Iron deficiency in blood donors: A national cross-sectional study","volume":"54","author":"Salvin","year":"2014","journal-title":"Transfusion"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J., Kolnagou, A., Demetriou, T., Neocleous, M., and Kontoghiorghe, C.N. (2021). New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115546"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2174\/1389450119666180605112235","article-title":"Pathological Roles of Iron in Cardiovascular Disease","volume":"19","author":"Kobayashi","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"ref_125","first-page":"365","article-title":"Knowledge, Attitude and Practice towards Dietary Iron among Patients with Thalassemia and Their Caregivers in Peninsular Malaysia","volume":"74","author":"Man","year":"2019","journal-title":"Med. J. Malays"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e2020041","DOI":"10.4084\/mjhid.2020.041","article-title":"Iron Deficiency Anemia in Children Residing in High and Low-Income Countries: Risk Factors, Prevention, Diagnosis and Therapy","volume":"12","author":"Mantadakis","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4103\/jfmpc.jfmpc_1062_19","article-title":"Prevalence of anaemia and its association with dietary habits among pregnant women in the urban area of Haryana","volume":"9","author":"Grover","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/157339631130900008","article-title":"Is red meat required for the prevention of iron deficiency among children and adolescents?","volume":"10","author":"Savva","year":"2014","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Wessells, K.R., Young, R.R., Ferguson, E.L., Ou\u00e9draogo, C.T., Faye, M.T., and Hess, S.Y. (2019). Assessment of Dietary Intake and Nutrient Gaps, and Development of Food-Based Recommendations, Among Pregnant and Lactating Women in Zinder, Niger: An Optifood Linear Programming Analysis. Nutrients, 11.","DOI":"10.3390\/nu11010072"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3945\/ajcn.117.156034","article-title":"Dietary Iron Intake, Iron Status, and Gestational Diabetes","volume":"106","author":"Zhang","year":"2017","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_131","first-page":"77","article-title":"Relationships among iron accumulation, cirrhosis, and hepatitis B virus infection in Bantu siderosis","volume":"69","author":"Senba","year":"1989","journal-title":"Ann. Soc. Belg. Med. Trop."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1191\/0960327105ht564oa","article-title":"Hepatotoxicity in acute iron poisoning","volume":"24","author":"Robertson","year":"2005","journal-title":"Hum. Exp. Toxicol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/dietetics2010001","article-title":"Diet Quality, Nutritional Adequacy and Anthropometric Status among Indigenous Women of Reproductive Age Group (15\u201349 Years) in India: A Narrative Review","volume":"2","author":"Kapoor","year":"2022","journal-title":"Dietetics"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1206090","DOI":"10.3389\/fnut.2023.1206090","article-title":"Analysis of the nutritional status in the Palestinian territory: A review study","volume":"10","author":"Assaf","year":"2023","journal-title":"Front. Nutr."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-physiol-022522-102832","article-title":"Iron and the Pathophysiology of Diabetes","volume":"85","author":"Harrison","year":"2023","journal-title":"Annu. Rev. Physiol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.tem.2022.06.004","article-title":"Iron effects versus metabolic alterations in hereditary hemochromatosis driven bone loss","volume":"33","author":"Baschant","year":"2022","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Calori, S., Comisi, C., Mascio, A., Fulchignoni, C., Pataia, E., Maccauro, G., Greco, T., and Perisano, C. (2023). Overview of Ankle Arthropathy in Hereditary Hemochromatosis. Med. Sci., 11.","DOI":"10.3390\/medsci11030051"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Ahmed, S., Peterson, S.J., Parikh, M.A., and Frishman, W.H. (2023). Cardiovascular Manifestations of Hemochromatosis: A Review of Pathophysiology, Mechanisms, and Treatment Options. Cardiol. Rev.","DOI":"10.1097\/CRD.0000000000000622"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.4254\/wjh.v14.i9.1804","article-title":"Hereditary hemochromatosis: Temporal trends, sociodemographic characteristics, and independent risk factor of hepatocellular cancer\u2014Nationwide population-based study","volume":"14","author":"Haider","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/03630269.2010.486335","article-title":"Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: Regulatory and non regulatory mechanisms of increased iron absorption","volume":"34","author":"Kontoghiorghes","year":"2010","journal-title":"Hemoglobin"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(79)92175-5","article-title":"Iron absorption and loading in beta-thalassaemia intermedia","volume":"2","author":"Pippard","year":"1979","journal-title":"Lancet"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.V71.4.1124.1124","article-title":"The effect of erythroid hyperplasia on iron balance","volume":"71","author":"Pootrakul","year":"1988","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2147\/DDDT.S79458","article-title":"Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes","volume":"10","author":"Kontoghiorghe","year":"2016","journal-title":"Drug Des. Devel Ther."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2023). Iron Load Toxicity in Medicine: From Molecular and Cellular Aspects to Clinical Implications. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612928"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Kolnagou, A., Kleanthous, M., and Kontoghiorghes, G.J. (2022). Benefits and Risks in Polypathology and Polypharmacotherapy Challenges in the Era of the Transition of Thalassaemia from a Fatal to a Chronic or Curable Disease. Front. Biosci., 14.","DOI":"10.31083\/j.fbe1403018"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.cll.2023.07.002","article-title":"Transfusion Support of Patients with Myelodysplastic Syndromes","volume":"43","author":"Guarente","year":"2023","journal-title":"Clin. Lab. Med."},{"key":"ref_147","first-page":"213","article-title":"Risk of Streptococcus pneumoniae-associated haemolytic uraemic syndrome in industrialised nations: A systematic review of the literature","volume":"72","author":"Lok","year":"2023","journal-title":"Epidemiol. Mikrobiol. Imunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12967-023-04824-x","article-title":"Red blood cell-derived arginase release in hemolytic uremic syndrome","volume":"22","author":"Friberg","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_149","unstructured":"Anderson, F.W., and Hiller, M.C. (1975). Development of Iron Chelators for Clinical Use, DHEW. DHEW Publication No. (NIH) 77-994;."},{"key":"ref_150","unstructured":"Kontoghiorghes, G.J. (1982). The Design of Orally Active Iron Chelators for the Treatment of Thalassaemia. [Ph.D. Thesis, University of Essex]. Available online: https:\/\/www.pri.ac.cy\/files\/KGJ_thesis_1982.pdf."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1749-6632.1990.tb24321.x","article-title":"Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia","volume":"612","author":"Kontoghiorghes","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2174\/0929867043364685","article-title":"The design and development of deferiprone (L1) and other iron chelators for clinical use: Targeting methods and application prospects","volume":"11","author":"Kontoghiorghes","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.2174\/092986705774463003","article-title":"Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combination","volume":"12","author":"Kontoghiorghes","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/acschembio.8b01100","article-title":"Transferrin Cycle and Clinical Roles of Citrate and Ascorbate in Improved Iron Metabolism","volume":"14","author":"Levina","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s10534-018-0142-2","article-title":"Ferric pyrophosphate citrate: Interactions with transferrin","volume":"31","author":"Pratt","year":"2018","journal-title":"Biometals"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dkz225","article-title":"Adjunctive transferrin to reduce the emergence of antibiotic resistance in Gram-negative bacteria","volume":"74","author":"Luna","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1517\/13543784.2013.787408","article-title":"Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals","volume":"22","author":"Kontoghiorghe","year":"2013","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1039\/c8mt00308d","article-title":"Competition between Al3+ and Fe3+ binding to human transferrin and toxicological implications: Structural investigations using ultra-high resolution ESI MS and CD spectroscopy","volume":"11","author":"Ott","year":"2019","journal-title":"Metallomics"},{"key":"ref_159","first-page":"301.e1","article-title":"Lactoferrin: Structure, function and applications","volume":"33","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1080\/10408398.2017.1381583","article-title":"Lactoferrin: Structure, function, denaturation and digestion","volume":"59","author":"Wang","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e02284-19","DOI":"10.1128\/AAC.02284-19","article-title":"Lactoferrin Is Broadly Active against Yeasts and Highly Synergistic with Amphotericin B","volume":"64","author":"Fernandes","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Rosa, L., Cutone, A., Lepanto, M.S., Paesano, R., and Valenti, P. (2017). Lactoferrin: A Natural Glycoprotein Involved in Iron and Inflammatory Homeostasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091985"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Van Gorkom, G.N.Y., Lookermans, E.L., Van Elssen, C.H.M.J., and Bos, G.M.J. (2019). The effect of vitamin C (Ascorbic acid) in the treatment of patients with cancer: A systematic review. Nutrients, 11.","DOI":"10.3390\/nu11050977"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jama.2019.21984","article-title":"Vitamin C for Sepsis and Acute Respiratory Failure","volume":"323","author":"Hager","year":"2020","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/bcpt.12323","article-title":"Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: A pharmacokinetic evaluation","volume":"116","author":"Nielsen","year":"2015","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Hemil\u00e4, H., and Chalker, E. (2023). Vitamin C reduces the severity of common colds: A meta-analysis. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-17229-8"},{"key":"ref_167","first-page":"e49308","article-title":"Dietary Sources, Bioavailability, and Functions of Ascorbic Acid (Vitamin C) and Its Role in the Common Cold, Tissue Healing, and Iron Metabolism","volume":"15","author":"Bhoot","year":"2023","journal-title":"Cureus"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J., Kolnagou, A., Kontoghiorghe, C.N., Mourouzidis, L., Timoshnikov, V.A., and Polyakov, N.E. (2020). Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications. Medicines, 7.","DOI":"10.3390\/medicines7080045"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/1570161121666230911115725","article-title":"Role of Vitamins in Cardiovascular Health: Know Your Facts-Part 2","volume":"21","author":"Manolis","year":"2023","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Timoshnikov, V.A., Selyutina, O.Y., Polyakov, N.E., Didichenko, V., and Kontoghiorghes, G.J. (2022). Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant\/Pro-Oxidant Activity and Applications in Medicine. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031247"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bcmd.2018.12.002","article-title":"Favourable Improvement in Haematological Parameters in Response to Oral Iron and Vitamin C Combination in Children with Iron Refractory Iron Deficiency Anemia (IRIDA) Phenotype","volume":"75","author":"Sourabh","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s12011-013-9797-2","article-title":"Is a 40% Absorption of Iron from a Ferrous ascorbate Reference Dose Appropriate to Assess Iron Absorption Independent of Iron Status?","volume":"155","author":"Valenzuela","year":"2013","journal-title":"Biol. Trace Elem. Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s12098-019-03068-2","article-title":"Comparison of Therapeutic Efficacy of Ferrous Ascorbate and Iron Polymaltose Complex in Iron Deficiency Anemia in Children: A Randomized Controlled Trial","volume":"86","author":"Patil","year":"2019","journal-title":"Indian J. Pediatr."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ejh.12594","article-title":"Role of vitamin C as an adjuvant therapy to different iron chelators in young \u03b2-thalassemia major patients: Efficacy and safety in relation to tissue iron overload","volume":"96","author":"Elalfy","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000206370","article-title":"Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis","volume":"72","author":"Conte","year":"1984","journal-title":"Acta Haematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12013-009-9043-x","article-title":"A review of the antioxidant mechanisms of polyphenol compounds related to iron binding","volume":"53","author":"Perron","year":"2009","journal-title":"Cell Biochem. Biophys."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.foodchem.2010.08.012","article-title":"The molecular basis of working mechanism of natural polyphenolic antioxidants","volume":"125","author":"Leopoldini","year":"2011","journal-title":"Food Chem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctim.2019.02.017","article-title":"The effect of quercetin on iron overload and inflammation in \u03b2-thalassemia major patients: A double-blind randomized clinical trial","volume":"46","author":"Azarkeivan","year":"2019","journal-title":"Complement. Ther. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejmech.2018.12.016","article-title":"The therapeutic potential of curcumin: A review of clinical trials","volume":"163","author":"Salehi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s12325-020-01251-y","article-title":"Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review","volume":"37","author":"Gillessen","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"26723","DOI":"10.1074\/jbc.270.45.26723","article-title":"Siderophores: Structure and function of microbial iron transport compounds","volume":"270","author":"Neilands","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.molmed.2016.10.005","article-title":"Siderophores in Iron Metabolism: From Mechanism to Therapy Potential","volume":"22","author":"Wilson","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"S529","DOI":"10.1093\/cid\/ciz825","article-title":"The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics","volume":"69","author":"Page","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cca.2019.11.029","article-title":"Iron overload: Effects on cellular biochemistry","volume":"504","author":"Sousa","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Consoli, V., Sorrenti, V., Grosso, S., and Vanella, L. (2021). Heme Oxygenase-1 Signaling and Redox Homeostasis in Physiopathological Conditions. Biomolecules, 11.","DOI":"10.3390\/biom11040589"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1152\/physrev.00011.2005","article-title":"Heme oxygenase-1\/carbon monoxide: From basic science to therapeutic applications","volume":"86","author":"Ryter","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.pcl.2018.02.005","article-title":"Red Blood Cell Enzyme Disorders","volume":"65","author":"Grace","year":"2018","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1573396320666230727102042","article-title":"Iron deficiency anemia: An updated review","volume":"20","author":"Leung","year":"2023","journal-title":"Curr. Pediatr. Rev."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Xing, Y., Gao, S., Zhang, X., and Zang, J. (2022). Dietary Heme-Containing Proteins: Structures, Applications, and Challenges. Foods, 11.","DOI":"10.3390\/foods11223594"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"20441","DOI":"10.1021\/acsomega.2c01833","article-title":"Iron Absorption: Factors, Limitations, and Improvement Methods","volume":"7","author":"Piskin","year":"2022","journal-title":"ACS Omega"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(15)00444-1","article-title":"Carcinogenicity of Consumption of Red and Processed Meat","volume":"16","author":"Bouvard","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/104454902753759717","article-title":"Hemopexin: Structure, Function, and Regulation","volume":"21","author":"Tolosano","year":"2002","journal-title":"DNA Cell Boil."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ajh.23623","article-title":"Haptoglobin testing in hemolysis: Measurement and interpretation","volume":"89","author":"Shih","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_194","first-page":"1332","article-title":"Chelators affecting iron absorption in mice","volume":"40","author":"Kontoghiorghes","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0041-008X(71)90300-0","article-title":"8-hydroxyquinoline: Chronic toxicity and inhibitory effect on the carcinogenicity of N-2- fluorenylacetamide","volume":"19","author":"Yamamoto","year":"1971","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00134-013-3108-4","article-title":"Acute iron intoxication: Change in urine color during chelation therapy with deferoxamine","volume":"40","author":"Castro","year":"2014","journal-title":"Intensive Care Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3109\/0886022X.2013.790299","article-title":"Successful treatment of severe iron intoxication with gastrointestinal decontamination, deferoxamine, and hemodialysis","volume":"35","author":"Gumber","year":"2013","journal-title":"Ren. Fail."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.V48.6.923.923","article-title":"The effect of chelating agents on iron mobilization in Chang cell cultures","volume":"48","author":"White","year":"1976","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1600-0609.1987.tb00776.x","article-title":"Variation in iron accumulation, transferrin membrane binding and DNA synthesis in the K-562 and U-937 cell lines induced by chelators and their iron complexes","volume":"39","author":"Forsbeck","year":"1987","journal-title":"Eur. J. Haematol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0020-1693(00)91889-9","article-title":"Structure\/red blood cell permeability activity of iron (III) chelator complexes","volume":"151","author":"Kontoghiorghes","year":"1988","journal-title":"Inorganica Chim. Acta"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/ejh.12939","article-title":"The aim of iron chelation therapy in thalassaemia","volume":"99","author":"Kontoghiorghes","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_202","first-page":"27","article-title":"Advances in oral iron chelation in man","volume":"55","author":"Kontoghiorghes","year":"1992","journal-title":"Int. J. Hematol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2014-07-586677","article-title":"Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload","volume":"125","author":"Aydinok","year":"2015","journal-title":"Blood"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ejh.12507","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients","volume":"95","author":"Elalfy","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1365-2125.1991.tb05525.x","article-title":"Iron supplements: A common cause of drug interactions","volume":"31","author":"Campbell","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_206","first-page":"150","article-title":"The effect of tetracycline administration on iron absorption in mice","volume":"35","author":"Djaldetti","year":"1981","journal-title":"Biomedicine"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0190-9622(85)80041-4","article-title":"Absorption of minocycline hydrochloride and tetracycline hydrochloride: Effect of food, milk, and iron","volume":"12","author":"Leyden","year":"1985","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00775-023-02018-w","article-title":"The formation of Fe3+-doxycycline complex is pH dependent: Implications to doxycycline bioavailability","volume":"28","year":"2023","journal-title":"J. Biol. Inorg. Chem."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/M23-0675","article-title":"Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly: A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial","volume":"176","author":"McQuilten","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1089\/ars.2012.4795","article-title":"Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection","volume":"18","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/nbu.12643","article-title":"Factors affecting iron absorption and the role of fortification in enhancing iron levels","volume":"48","author":"Perera","year":"2023","journal-title":"Nutr. Bull."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/aogs.14607","article-title":"Iron supplements in pregnant women with normal iron status: A systematic review and meta-analysis","volume":"102","author":"Hansen","year":"2023","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/dom.14886","article-title":"Impact of iron supplementation on gestational diabetes mellitus: A literature review","volume":"25","author":"Liu","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12970-015-0099-2","article-title":"Iron and the female athlete: A review of dietary treatment methods for improving iron status and exercise performance","volume":"12","author":"Alaunyte","year":"2015","journal-title":"J. Int. Soc. Sports Nutr."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/jn\/nxz042","article-title":"The Chemical Forms of Iron in Commercial Prenatal Supplements Are Not Always the Same as Those Tested in Clinical Trials","volume":"149","author":"Saldanha","year":"2019","journal-title":"J. Nutr."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2023). Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054970"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1998.00380.x","article-title":"Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron","volume":"12","author":"Harvey","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/000456320003700405","article-title":"Assessment of iron absorption from ferric trimaltol","volume":"37","author":"Reffitt","year":"2000","journal-title":"Ann. Clin. Biochem."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1517\/14656566.2015.1096929","article-title":"Ferric maltol (ST10): A novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease","volume":"16","author":"Stallmach","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1060028020941014","article-title":"Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults","volume":"55","author":"Khoury","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s13318-016-0334-5","article-title":"Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency","volume":"42","author":"Bokemeyer","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MIB.0000000000000314","article-title":"AEGIS Study Group. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: Results from a phase-3 clinical trial program","volume":"21","author":"Gasche","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apt.13665","article-title":"Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: Long-term extension data from a Phase 3 study","volume":"44","author":"Schmidt","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_224","first-page":"70","article-title":"AEGIS-CKD Study Group. Efficacy and safety of oral ferric maltol (FM) in treating iron-deficiency anemia (IDA) in patients with CKD: Randomized controlled trial [FR-OR120]","volume":"29","author":"Kopyt","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2000616","DOI":"10.1183\/13993003.00616-2020","article-title":"Oral iron supplementation with ferric maltol in patients with pulmonary hypertension","volume":"56","author":"Olsson","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_226","first-page":"183","article-title":"Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells","volume":"3","author":"Kontoghiorghes","year":"1990","journal-title":"BioMetals"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ccr3.2595","article-title":"Recurrent severe hypophosphatemia following intravenous iron administration","volume":"8","author":"Nataatmadja","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/j.ackd.2019.05.001","article-title":"Long-Term Risks of Intravenous Iron in End-Stage Renal Disease Patients","volume":"26","author":"Kshirsagar","year":"2019","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"100873","DOI":"10.1016\/j.mam.2020.100873","article-title":"Iron deficiency and supplementation in heart failure and chronic kidney disease","volume":"75","author":"Punj","year":"2020","journal-title":"Mol. Asp. Med."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CIA.S58394","article-title":"Ulceration of the oral mucosa following direct contact with ferrous sulfate in elderly patients: A case report and a review of the French National Pharmacovigilance Database","volume":"9","author":"Liabeuf","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.biopha.2012.06.003","article-title":"Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate","volume":"66","author":"Ferrari","year":"2012","journal-title":"Biomed. Pharmacother."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2023). Drug Selection and Posology, Optimal Therapies and Risk\/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316749"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1248\/cpb.22.1008","article-title":"Studies on passiflora incarnata dry extract. I. Isolation of maltol and pharmacological action of maltol and ethyl maltol","volume":"22","author":"Aoyagi","year":"1974","journal-title":"Chem. Pharm. Bull."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"11179","DOI":"10.1021\/acs.jafc.9b04800","article-title":"Quantitative Analyses of Key Odorants and Their Precursors Reveal Differences in the Aroma of Gluten-Free Rice Bread and Wheat Bread","volume":"67","author":"Rohleder","year":"2019","journal-title":"J. Agric. Food Chem."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1021\/jf60173a036","article-title":"The metabolism of ethyl maltol and maltol in the dog","volume":"19","author":"Rennhard","year":"1971","journal-title":"J. Agric. Food Chem."},{"key":"ref_236","first-page":"281","article-title":"Gallium Complexes as Anticancer Drugs","volume":"18","author":"Chitambar","year":"2018","journal-title":"Met. Ions Life Sci."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2460\/ajvr.71.11.1371","article-title":"Pharmacokinetics of gallium maltolate after intragastric administration in adult horses","volume":"71","author":"Arnold","year":"2010","journal-title":"Am. J. Vet. Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"e2020011","DOI":"10.4084\/mjhid.2020.011","article-title":"The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia","volume":"12","author":"Kontoghiorghes","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03630260701726491","article-title":"Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone","volume":"32","author":"Kolnagou","year":"2008","journal-title":"Hemoglobin"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(89)90264-X","article-title":"Survival and causes of death in thalassaemia major","volume":"334","author":"Zurlo","year":"1989","journal-title":"Lancet"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1532-429X-10-42","article-title":"Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance","volume":"10","author":"Modell","year":"2008","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_242","first-page":"1187","article-title":"Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980\u20132004","volume":"91","author":"Telfer","year":"2006","journal-title":"Haematologica"},{"key":"ref_243","first-page":"261","article-title":"A synopsis of current care of thalassaemia major patients in Hong Kong","volume":"17","author":"Au","year":"2011","journal-title":"Hong Kong Med. J."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bcmd.2011.07.002","article-title":"Iron chelation therapy in thalassemia major: A systematic review with meta-analyses of 1520 patients included on randomized clinical trials","volume":"47","author":"Maggio","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/BF02723953","article-title":"Burden of genetic disorders in India","volume":"67","author":"Verma","year":"2000","journal-title":"Indian J. Pediatr."},{"key":"ref_246","first-page":"95","article-title":"The impact and disease burden of thalassemia in Thailand: A population-based study in 2010","volume":"95","author":"Teawtrakul","year":"2012","journal-title":"J. Med. Assoc. Thail."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5662\/wjm.v4.i4.197","article-title":"Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases","volume":"4","author":"Kolnagou","year":"2014","journal-title":"World J. Methodol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"e35455","DOI":"10.1097\/MD.0000000000035455","article-title":"Successful chelation in beta-thalassemia major in the 21st century","volume":"102","author":"Fragodimitri","year":"2023","journal-title":"Medicine"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1532\/IJH97.E0637","article-title":"Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine","volume":"86","author":"Aessopos","year":"2007","journal-title":"Int. J. Hematol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1517\/14740330903535845","article-title":"Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases","volume":"9","author":"Kontoghiorghes","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/BF02662506","article-title":"T2 relaxation time study of iron overload in b-thalassemia","volume":"6","author":"Mavrogeni","year":"1998","journal-title":"Magn. Reson. Mater. Phys. Biol. Med."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0609.2010.01499.x","article-title":"Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone\/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy","volume":"85","author":"Kolnagou","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2141.2009.07970.x","article-title":"Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major","volume":"148","author":"Farmaki","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1055\/s-0043-102691","article-title":"Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination","volume":"67","author":"Kolnagou","year":"2017","journal-title":"Drug Res."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2741\/4634","article-title":"Chelation protocols for the elimination and prevention of iron overload in thalassaemia","volume":"23","author":"Kolnagou","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MPH.0000000000001596","article-title":"Evaluation of Efficacy, Safety, and Satisfaction Taking Deferasirox Twice Daily Versus Once Daily in Patients With Transfusion-Dependent Thalassemia","volume":"42","author":"Karimi","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.15595","article-title":"MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine","volume":"183","author":"Pepe","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/17474086.2019.1593823","article-title":"Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major\u2014A pilot study","volume":"12","author":"Lin","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MPH.0000000000000780","article-title":"Efficacy and Safety of Combined Oral Chelation With Deferiprone and Deferasirox in Children With \u03b2-Thalassemia Major: An Experience From North India","volume":"39","author":"Parakh","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.transci.2019.03.021","article-title":"A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major","volume":"58","author":"Eghbali","year":"2019","journal-title":"Transfus. Apher. Sci."},{"key":"ref_261","unstructured":"(2015, December 01). Exjade (Deferasirox) Tablets for Oral Suspension. Prescribing Information. (Novartis Pharmaceutical Corporation USA (NDA 21\u2013882). October 2006; pp. 1\u201312. Changes to the Warnings and Adverse Reactions Sections, Available online: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/briefing\/2005-4177B1_02_b.pdf."},{"key":"ref_262","unstructured":"(2015, December 01). Exjade (Deferasirox) Tablets for Oral Suspension (Highlights of Prescribing Information. Novartis Pharmaceutical Corp. USA (T2011-106). August 2011; pp. 1\u201316), Available online: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021882s010lbl.pdf."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/03630269.2011.576906","article-title":"A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: Insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients","volume":"35","author":"Kontoghiorghes","year":"2011","journal-title":"Hemoglobin"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1517\/14740338.2013.799664","article-title":"A record number of fatalities in many categories of patients treated with deferasirox: Loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?","volume":"12","author":"Kontoghiorghes","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"5461617","DOI":"10.1155\/2019\/5461617","article-title":"Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study","volume":"2019","author":"Badeli","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0272-6386(12)80606-8","article-title":"Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry","volume":"18","author":"Boelaert","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/IAE.0b013e3181679f67","article-title":"Deferoxamine-related ocular toxicity: Incidence and outcome in a pediatric population","volume":"28","author":"Baath","year":"2008","journal-title":"Retina"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00043426-199703000-00008","article-title":"Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment","volume":"19","author":"Levine","year":"1997","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(81)92227-3","article-title":"Rapid desensitisation for desferrioxamine anaphylactic reaction","volume":"317","author":"Miller","year":"1981","journal-title":"Lancet"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/S0140-6736(83)91136-4","article-title":"Desferrioxamine and systemic yersiniosis","volume":"322","author":"Pipic","year":"1983","journal-title":"Lancet"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ajh.20103","article-title":"Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model","volume":"76","author":"Chan","year":"2004","journal-title":"Am. J. Hematol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2141.2000.01866.x","article-title":"Safety profile of the oral iron chelator deferiprone: A multicentre study","volume":"108","author":"Cohen","year":"2000","journal-title":"Br. J. Haematol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2006-12-065433","article-title":"Selective iron chelation in Friedreich ataxia: Biologic and clinical implications","volume":"110","author":"Boddaert","year":"2007","journal-title":"Blood"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2011.043018","article-title":"A pilot trial of deferiprone for neurodegeneration with brain iron accumulation","volume":"96","author":"Abbruzzese","year":"2011","journal-title":"Haematologica"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","article-title":"Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease","volume":"7","author":"Ward","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_276","first-page":"522","article-title":"Studies of aluminium mobilization in renal dialysis patients using the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one","volume":"44","author":"Kontoghiorghes","year":"1994","journal-title":"Arzneimittelforschung"},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"Romano, N., Baiardi, G., Pinto, V.M., Quintino, S., Gianesin, B., Sasso, R., Diociasi, A., Mattioli, F., Marchese, R., and Abbruzzese, G. (2022). Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154524"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/15376516.2012.730558","article-title":"Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease","volume":"23","author":"Rajapurkar","year":"2013","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_279","first-page":"17","article-title":"Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria","volume":"115","author":"Mohanty","year":"2002","journal-title":"Indian J. Med. Res."},{"key":"ref_280","doi-asserted-by":"crossref","unstructured":"Saxena, D., Spino, M., Tricta, F., Connelly, J., Cracchiolo, B.M., Hanauske, A.R., D\u2019Alliessi Gandolfi, D., Mathews, M.B., Karn, J., and Holland, B. (2016). Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154842"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0140-6736(89)92011-4","article-title":"Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients","volume":"334","author":"Vreugdenhil","year":"1989","journal-title":"Lancet"},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","article-title":"Trial of Deferiprone in Parkinson\u2019s Disease","volume":"387","author":"Devos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_283","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J. (2023). The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases. Pharmaceuticals, 16.","DOI":"10.3390\/ph16071016"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.3945\/jn.110.125369","article-title":"Polyphenols and phytic acid contribute to the low iron bioavailability from common beans in young women","volume":"140","author":"Petry","year":"2010","journal-title":"J. Nutr."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1750-3841.2010.01796.x","article-title":"Dietary ligands as determinants of iron-zinc interactions at the absorptive enterocyte","volume":"75","author":"Iyengar","year":"2010","journal-title":"J. Food Sci."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/09637480903213649","article-title":"Role of oxate, phytate, tannins and cooking on iron bioavailability from foods commonly consumed in Mexico","volume":"61","author":"Sotelo","year":"2010","journal-title":"Int. J. Food Sci. Nutr."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtemb.2014.11.005","article-title":"Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium","volume":"30","author":"Jaramillo","year":"2015","journal-title":"J. Trace Elem. Med. Biol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1039\/b416256k","article-title":"Metal complexes of maltol and close analogues in medicinal inorganic chemistry","volume":"35","author":"Thompson","year":"2006","journal-title":"Chem. Soc. Rev."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1021\/ic9004642","article-title":"Mixed-ligand copper(II) maltolate complexes: Synthesis, characterization, DNA binding and cleavage, and cytotoxicity","volume":"48","author":"Barve","year":"2009","journal-title":"Inorg. Chem."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1700699","DOI":"10.1002\/mnfr.201700699","article-title":"Gallic Acid and Gallates in Human Health and Disease: Do Mitochondria Hold the Key to Success?","volume":"62","author":"Kosuru","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00006231-200404000-00012","article-title":"99mTc-labelled human serum transferrin for tumour imaging: An in vitro and in vivo study of the complex","volume":"25","author":"Smith","year":"2004","journal-title":"Nucl. Med. Commun."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jlcr.3388","article-title":"A study of radiogallium aqueous chemistry: In vitro and in vivo characterisation of (67) Ga-hydrolysed-stannous fluoride particles","volume":"59","author":"Tsopelas","year":"2016","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3109\/00365521.2012.696682","article-title":"In-111 transferrin scintigraphy in cirrhosis with hypoalbuminemia: Evidence for protein-losing enteropathy in a small group of selected cases","volume":"47","author":"Dahlqvist","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_294","first-page":"1103","article-title":"Metal complexes of ruthenium: A potential class of selective anticancer drugs","volume":"11","author":"Sava","year":"1991","journal-title":"Anticancer. Res."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2174\/138920112802273245","article-title":"Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics","volume":"13","author":"Doroshow","year":"2012","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_296","first-page":"e37308","article-title":"Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines","volume":"15","author":"Rahimi","year":"2023","journal-title":"Cureus"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1038\/s41598-023-29964-4","article-title":"In vitro to clinical translational pharmacokinetic\/pharmacodynamic modeling of doxorubicin (DOX) and dexrazoxane (DEX) interactions: Safety assessment and optimization","volume":"13","author":"Mody","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S2352-4642(22)00239-5","article-title":"Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"6","author":"Mulder","year":"2022","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1128\/AAC.47.6.1805-1817.2003","article-title":"Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors","volume":"47","author":"Niewerth","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.2174\/1381612822666160530151209","article-title":"Repositioning the Old Fungicide Ciclopirox for New Medical Uses","volume":"22","author":"Shen","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.23640","article-title":"Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies","volume":"89","author":"Minden","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/15376516.2012.730562","article-title":"EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: Review of preliminary findings and risk\/benefit assessment","volume":"23","author":"Born","year":"2013","journal-title":"Toxicol. Mech. Methods"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/03630269.2011.578950","article-title":"Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: Implications on toxicity and therapeutic strategies","volume":"35","author":"Konstantinou","year":"2011","journal-title":"Hemoglobin"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.seminhematol.2018.04.008","article-title":"Fetal Hemoglobin Induction by Epigenetic Drugs","volume":"55","author":"Lavelle","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3109\/08880010903271671","article-title":"Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: Case series and review of literature","volume":"26","author":"Ehsani","year":"2009","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_306","doi-asserted-by":"crossref","unstructured":"Fraser, D.I., Liu, K.T., Reid, B.J., Hawkins, E., Sevier, A., Pyle, M., Robinson, J.W., Ouellette, P.H., and Ballantyne, J.S. (2015). Widespread Natural Occurrence of Hydroxyurea in Animals. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0142890"},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/bjh.16272","article-title":"Safety and effectiveness of thalidomide and hydroxyurea combination in \u03b2-thalassaemia intermedia and major: A retrospective pilot study","volume":"188","author":"Shah","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajh.27189","article-title":"Reduction of extramedullary erythropoiesis and amelioration of anemia in a \u03b2-thalassemia patient treated with thalidomide","volume":"99","author":"Pinto","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"102544","DOI":"10.1016\/j.bcmd.2021.102544","article-title":"Comparison of efficacy and safety of thalidomide vs. hydroxyurea in patients with Hb E-\u03b2 thalassemia\u2014A pilot study from a tertiary care Centre of India","volume":"88","author":"Jain","year":"2021","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/ajh.27102","article-title":"Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia","volume":"99","author":"Garbowski","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood.2023021839","article-title":"Splenic iron decreases without change in volume or liver parameters during luspatercept therapy","volume":"142","author":"Denton","year":"2023","journal-title":"Blood"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): Interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"key":"ref_313","doi-asserted-by":"crossref","unstructured":"Longo, F., Motta, I., Pinto, V., Piolatto, A., Ricchi, P., Tartaglione, I., and Origa, R. (2023). Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072584"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1141603","DOI":"10.3389\/fonc.2023.1141603","article-title":"Distinctive modulation of hepcidin in cancer and its therapeutic relevance","volume":"13","author":"Lin","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12672-023-00637-y","article-title":"Targeting iron metabolism in osteosarcoma","volume":"14","author":"Ma","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/nu6010249","article-title":"Iron Transport through Ferroportin Is Induced by Intracellular Ascorbate and Involves IRP2 and HIF2\u03b1","volume":"6","author":"Scheers","year":"2014","journal-title":"Nutrients"},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(23)00330-2","article-title":"Profiling the dysregulated immune response in sepsis: Overcoming challenges to achieve the goal of precision medicine","volume":"12","author":"Cajander","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.52586\/5064","article-title":"The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic","volume":"26","author":"Kontoghiorghes","year":"2021","journal-title":"Front. Biosci."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ajh.2830420403","article-title":"Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload","volume":"42","author":"Kontoghiorghes","year":"1993","journal-title":"Am. J. Hematol."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"e071335","DOI":"10.1136\/bmjopen-2022-071335","article-title":"Drug exposure during pregnancy in primary care: An algorithm and observational study from SIDIAP database, Catalunya, Spain","volume":"13","author":"Marsal","year":"2023","journal-title":"BMJ Open"},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11095-015-1805-0","article-title":"Model-Based Optimisation of Deferoxamine Chelation Therapy","volume":"33","author":"Bellanti","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_322","doi-asserted-by":"crossref","unstructured":"Ferih, K., Elsayed, B., Elshoeibi, A.M., Elsabagh, A.A., Elhadary, M., Soliman, A., Abdalgayoom, M., and Yassin, M. (2023). Applications of Artificial Intelligence in Thalassemia: A Comprehensive Review. Diagnostics, 13.","DOI":"10.3390\/diagnostics13091551"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/17512433.2023.2294005","article-title":"Artificial intelligence and machine learning in clinical pharmacological research","volume":"17","author":"Mayer","year":"2024","journal-title":"Expert Rev. Clin. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4654\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:33:40Z","timestamp":1760106820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/9\/4654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":323,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["ijms25094654"],"URL":"https:\/\/doi.org\/10.3390\/ijms25094654","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}